Brochure
18 Oct 2024
Cayman Pharma cGMP API Manufacturing
PDF 564 kB
This leaflet presents cGMP API portfolio of Cayman Pharma and Cayman Chemical.
Content provided by our supplier
Cayman Pharma s.r.o
-
CZ -
2015On CPHI since
-
3Certificates
-
100 - 249Employees
Company types
Primary activities
Other Content from Cayman Pharma s.r.o (1)
-
News Cayman Chemical Receives CEP for Latanoprost API from EDQM
ANN ARBOR, MI, SEPTEMBER 12, 2023—Cayman Chemical, a world leader in the manufacture of prostaglandins for both research use and as active pharmaceutical ingredients (APIs), has been granted a Certification of Suitability to the monographs of the European Pharmacopoeia (CEP) by the European Directorate for the Quality of Medicines and HealthCare (EDQM) for its latanoprost API, effective August 28th, 2023. Cayman Chemical is the first company in the USA to receive a CEP for latanoprost.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance